2024 Asia Conference on Lung Cancer (ACLC) - Poster & ePosters-PP02.36

PP02.36 - Yinnan Meng

Pdf Summary

This real-world study assessed the risk of treatment-related pneumonitis (TRP) in patients with non-small cell lung cancer (NSCLC) undergoing thoracic radiotherapy (RT) combined with tyrosine kinase inhibitors (TKIs) in Hong Kong. Data were sourced from the Clinical Data Analysis and Reporting System (CDARS), covering patient records from 43 public hospitals under the Hong Kong Hospital Authority between January 2010 and December 2023.<br /><br />The study included 245 eligible patients who received both thoracic RT and epidermal growth factor receptor (EGFR) TKIs, such as Gefitinib, Erlotinib, Afatinib, and Osimertinib. The primary endpoint was the incidence of grade 2 or higher (G2) pneumonitis, and the secondary endpoint was overall survival.<br /><br />The findings showed that 11.0% of patients experienced G2 pneumonitis, with three cases advancing to grade 3 (1.2%), but none progressing beyond this severity. Specifically, patients treated with definitive RT had higher pneumonitis rates (24.3% for G2 and 3.8% for G3) compared to those receiving local or palliative RT (4.7% for G2, none for G3).<br /><br />Osimertinib was associated with a symptomatic pneumonitis rate of 10.7%, showing no grade 3 or higher TRP incidences and having a similar safety profile to other TKIs.<br /><br />Additionally, no significant differences in overall survival were noted between symptomatic pneumonitis patients and others. The study concludes that in Hong Kong's real-world clinical setting, the combination of thoracic RT and EGFR TKIs results in a manageable pneumonitis incidence, with Osimertinib presenting no additional safety concerns.<br /><br />This research was supported by the Shenzhen Science and Technology Program, and the study adhered to ethical standards, with no conflicts of interest declared.

Keywords

non-small cell lung cancer

treatment-related pneumonitis

thoracic radiotherapy

tyrosine kinase inhibitors

epidermal growth factor receptor

Osimertinib

Gefitinib

Erlotinib

Afatinib

Hong Kong